

## IVERMECTIN FOR COVID-19

63 TRIALS, 613 SCIENTISTS, 26,398 PATIENTS

31 RANDOMIZED CONTROLLED TRIALS

86% IMPROVEMENT IN 14 PROPHYLAXIS TRIALS RR 0.14 [0.08-0.25]

73% IMPROVEMENT IN 27 EARLY TREATMENT TRIALS RR 0.27 [0.16-0.44]

40% IMPROVEMENT IN 22 LATE TREATMENT TRIALS RR 0.60 [0.48-0.76]


61% IMPROVEMENT IN 25 MORTALITY RESULTS RR 0.39 [0.28-0.56]

60% IMPROVEMENT IN 31 RANDOMIZED CONTROLLED TRIALS RR 0.40 [0.28-0.57]

SUMMARY OF RESULTS REPORTED IN IVERMECTIN TRIALS FOR COVID-19, 08/14/21, IVMETA.COM

IVERMECTIN SUCCESSFUL in Clinical Trials → MORE THAN 70% EFFECTIVE in 61 Studies

### Description



“Meta analysis using the most serious outcome reported shows 74% and 86% improvement for early treatment and prophylaxis (RR 0.26 [0.16-0.43] and 0.14 [0.08-0.25]), with similar results after exclusion based sensitivity analysis, restriction to peer-reviewed studies, restriction to serious outcomes, and restriction to Randomized Controlled Trials”

## Ivermectin for COVID-19: real-time meta analysis of 6

Covid Analysis, Aug 6, 2021, Version 106 — twitter personality response, added Mond

@CovidAnalysis [f](#) Share [T](#) Tweet PDF Studies Adoption Submit

- Meta analysis using the most serious outcome reported shows 74% and 86% improvement for e (RR 0.26 [0.16-0.43] and 0.14 [0.08-0.25]), with similar results after [exclusion based sensitivity](#) and [reviewed studies](#), restriction to [serious outcomes](#), and restriction to [Randomized Controlled Trials](#).
- 63% and 96% lower [mortality](#) is observed for early treatment and prophylaxis (RR 0.37 [0.16-0.88]). Statistically significant improvements are seen for [mortality](#), [hospitalization](#), [recovery](#), [cases](#), and [isolation](#). show statistically significant improvements in isolation.


	Studies	<a href="#">Prophylaxis</a>	<a href="#">Early treatment</a>	<a href="#">Late treatment</a>	Patients
<a href="#">All studies</a>	61	<b>86%</b> [75-92%]	<b>74%</b> [57-84%]	<b>43%</b> [26-56%]	23,309
<a href="#">With exclusions</a>	51	<b>88%</b> [76-94%]	<b>76%</b> [66-83%]	<b>50%</b> [28-65%]	18,907
<a href="#">Peer-reviewed</a>	42	<b>86%</b> [73-93%]	<b>75%</b> [61-84%]	<b>43%</b> [21-59%]	16,455
<a href="#">Randomized Controlled Trials</a>	30	<b>84%</b> [25-96%]	<b>67%</b> [54-76%]	<b>30%</b> [2-50%]	5,206
<a href="#">Mortality results</a>	23	<b>96%</b> [41-100%]	<b>63%</b> [12-84%]	<b>59%</b> [35-74%]	10,798

*Percentage improvement with ivermectin treatment*

- The probability that an ineffective treatment generated results as positive as the 61 studies to date is one in a billion ( $p = 0.0000000000028$ ).
- [Heterogeneity](#) arises from many factors including treatment delay, population, effect measured, and [Associations identified in pooled analysis are valid and underestimate the effect size for the optimal treatment](#). low in specific cases, for example early treatment mortality.
- While [many treatments](#) have some level of efficacy, they do not replace vaccines and other measures. 30% of ivermectin studies show zero events in the treatment arm.
- Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is sufficient for all current and future variants. All practical, effective, and safe means should be used. Those who delay treatments share responsibility for the increased risk of COVID-19 becoming endemic; and the increased morbidity and collateral damage.

more: <https://ivmmeta.com/>

The improvements are, as seen in the drop in Mortality rates, stunning results!



The protocol is at the Frontline Doctors website:

[I-MASK+ Protocol](#)

## Category

1. Main

## Tags

1. Donecká republika

2. Státní hranice
3. Státní hranice D?R
4. Ukrajina
5. Vitalij Kravec
6. Vladimír Bižovka

**Date Created**

08/26/2021